Device Trial Radar · NCT02169401
A Multi-centre Observational Study of the Axium Neurostimulator as a Treatment for Chronic Pain
Last checked: Nov 20, 2026Latest source record: Nov 14, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
135
Actual
Start
Nov 2012
Primary completion
Jan 25, 2017
Study completion Jan 25, 2017
Sponsor
- Lead sponsor
- Abbott Medical DevicesPublic (ABT)
- Sponsor type
- Industry
- First posted
- Jun 23, 2014
Design
- Study type
- Observational
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
08-SMI-2012 is a post market, observational, questionnaire based study to assess the effectiveness of the commercially available Axium neurostimulator in the management of intractable, chronic pain.
Conditions
- Chronic Pain
Interventions
Implantation with the commercially available Axium NeurostimulatorDevice
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pain Relief- Change in VAS Pain Intensity From Baseline to Post ImplantationTime frame: Post implantation at; 1, 3, 6, 12 and 24 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
James Cook University Hospital
Middlesbrough, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.